Navigation Links
RBC Life Sciences Reports Sales and Earnings Growth in 2010
Date:3/8/2011

IRVING, Texas, March 8, 2011 /PRNewswire/ -- (RBC Life Sciences: OTC Bulletin Board: RBCL) -- RBC Life Sciences, Inc., a provider of proprietary nutritional supplements, wound care and pain management products, today reported a 13% increase in consolidated net sales to $28.2 million for the year ended December 31, 2010, compared to net sales of $24.9 million for the same period during 2009. For 2010, the Company reported net earnings of $558,000, or $0.02 per diluted share, compared to a net loss of $335,000, or $0.02 per diluted share, during 2009.

"We significantly improved our financial performance in 2010 reporting sales growth in both our Nutritional Products segment and Medical Products segment," said RBC Life Sciences President and CEO, Clinton H. Howard.  "We were particularly pleased to report sales growth of 22% to our international licensees, which is our largest revenue channel.  This growth in sales along with expense reductions affected during 2010 resulted in an $893,000 improvement in net operating results and a return to profitability in 2010."

During 2010, net sales of Nutritional Products increased 15% to $21.6 million while net sales of Medical Products increased 6% to $6.5 million.

About RBC Life SciencesThrough wholly owned subsidiaries, RBC Life Sciences develops, manufactures and markets high-quality nutritional supplements and personal care products under its RBC Life brand to a growing population of consumers seeking wellness and a healthy lifestyle. Through its wholly owned subsidiary, MPM Medical, the Company also develops and markets to health care professionals in the United States proprietary prescription and nonprescription products for advanced wound care and pain management. All products are tested for quality assurance in-house, and by outside independent laboratories, to comply with regulations in the U.S. and in more than thirty countries in which the products are distributed. For more information, visit the company's Web site at www.rbclifesciences.com.

The statements above, other than statements of historical fact, may be forward-looking. Actual events will be dependent upon a number of factors and risks including, but not limited to, changes in plans by the Company's management, delays or problems in production, changes in the regulatory process, changes in market trends, and a number of other factors and risks described from time to time in the Company's filings with the Securities and Exchange Commission.RBC Life Sciences, Inc.Summary Results of Operations(in thousands, except per share data)

(unaudited)Years Ended December 31,20102009Net sales

$

28,157$

24,925Gross profit

13,68612,802Operating profit (loss)

1,044(160)Earnings (loss) before income taxes

891(324)Provision for income taxes

33311Net earnings (loss)

558(335)Earnings (loss) per share - basic

$

0.03$

(0.02)Earnings (loss) per share - diluted

0.02(0.02)Weighted average shares outstanding - basic

21,99921,921Weighted average shares outstanding - diluted

22,43621,921RBC Life Sciences, Inc.Condensed Consolidated Balance Sheets(in thousands)

(unaudited)December 31,20102009AssetsCash and cash equivalents

$

4,220$

3,972Inventories

5,3435,344Other current assets

1,6961,914Total current assets

11,25911,230Other assets

7,0857,383Total assets

$

18,344$

18,613Liabilities and shareholders' equityAccounts payable and accrued liabilities

$

3,087$

2,729Deferred revenue

2,4903,669Other current liabilities

168156Total current liabilities

5,7456,554Other liabilities

2,7232,840Shareholders' equity

9,8769,219Total liabilities and shareholders' equity

$

18,344$

18,613
'/>"/>

SOURCE RBC Life Sciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
2. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
3. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
4. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
5. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
6. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
7. Advanced Life Sciences Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma
8. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
9. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
10. Alfacell Corporation to Present at UBS Global Life Sciences Conference
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... PLEASANTON, Calif. , May 23, 2017 /PRNewswire/ ... world,s most innovative medical devices for pressure ulcer ... at the American Association of Critical Care Nurses, ... Houston May 22-25. The Leaf Patient ... designed specifically for the hospital environment.  The system ...
(Date:5/18/2017)... 18, 2017  Two Bayer U.S. Pharmaceutical leaders received ... its recent 28 th Woman of the ... showcases HBA,s longstanding mission of furthering the advancement and ... Cindy Powell-Steffen , senior director of brand ... and Libby Howe , a regional business manager ...
(Date:5/15/2017)... Enterin Inc., a privately-held CNS pharmaceutical company based in ... Parkinson,s disease (PD), has enrolled the first patient in the ... multicenter study involving patients with PD and taking place at ... 9-to-12-month period. The first stage is open label and involves ... include Denver , Boca Raton ...
Breaking Medicine Technology:
(Date:5/24/2017)... , ... May 24, 2017 , ... Myers Jackson is ... has the ability to sell luxury homes anywhere on the planet. The luxury home ... side from Hattiesburg to Houston city-scapes. A quick search of “11 Spyglass Hill Auction ...
(Date:5/24/2017)... (PRWEB) , ... May 24, 2017 , ... ... addition of ExtraHop to its solutions portfolio. ExtraHop delivers an analytics-first approach, layered ... of every IT system, from the datacenter to the cloud to the edge. ...
(Date:5/24/2017)... ... May 24, 2017 , ... The CFOs ... hospitals and health systems in the nation and help their organizations navigate the ... organizations and been instrumental in developing successful hospital and health system strategy. , ...
(Date:5/23/2017)... ... May 23, 2017 , ... MDLand International ... company, announced today that its iClinic V12.2 solution has achieved approval from National ... recently introduced PCMH 2017 standards which emphasize team-based care with a significant focus ...
(Date:5/23/2017)... ... 2017 , ... Cambridge, MA, May 23, 2017—Total costs per ... a Workers Compensation Research Institute (WCRI) study, a contrast from the increases of ... Benchmarks, 17th Edition looks at indemnity and medical payments for workers’ compensation ...
Breaking Medicine News(10 mins):